Undisclosed anti-CTLA4 antibody / Abzena - LARVOL DELTA

Tailoring Treatment Selection for Various Stages of NSCLC: Optimizing Patient Outcomes : Episode 14: Pros and Cons of Immunotherapy in Metastatic NSCLC (AJMC) - "Specialists assess the pros and cons of using immunotherapy in managing metastatic non-small cell lung cancer and delve into dosage variations and considerations when choosing different immunotherapy types."

Video

CRD5500: A versatile small molecule STING agonist amenable to bioconjugation as an ADC (AACR 2019) - "Interestingly, when Pre-Ab constructs that were not conjugated to antibody were delivered IV, they combined with an anti-CTLA4 antibody to eliminate tumors in the hSTING.CT26 syngenic tumor model. Conjugation with Trastuzumab was demonstrated and the ADC thus formed was screened in HER2 expressing cell lines.CONCLUSIONSThe ability of hSTING agonists to generate Type 1 IFN anti-tumor immune responses makes them a promising therapeutic option either as a single agent or in combination with other therapies.CRD5500 is a small molecule STING agonist that can be delivered in multiple formats making it well suited for further development as an anti-cancer agent."

IO Biomarker • Late-breaking abstract